Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares dropped to its lowest point since August 2023 after the disappointing trial r

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.